Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
BioGaia Pharma AB
Mallinckrodt Plc
PegBio Co Ltd
Shanghai Hanmai Biomedical Technology Co Ltd
Shionogi & Co Ltd
Yuhan Corp
Opioid-Induced Constipation (OIC) - Drug Profiles
BGP-345A - Drug Profile
Product Description
Mechanism Of Action
History of Events
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-02 - Drug Profile
Product Description
Mechanism Of Action
ldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-1902 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones
Featured News & Press Releases
Jan 26, 2022: BioGaia Pharma announces first patient enrolled in phase II clinical study evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Cada
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation
Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone)
Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation
Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation
Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Algesic Drug Products Advisory Committee Meeting’s Vote
May 06, 2014: Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Jourl
May 01, 2014: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Lubiprostone at Experimental Biology Conference 2014
Mar 12, 2014: Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functiol Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Opioid-Induced Constipation (OIC) - Pipeline by BioGaia Pharma AB, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Mallinckrodt Plc, 2022
Opioid-Induced Constipation (OIC) - Pipeline by PegBio Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shanghai Hanmai Biomedical Technology Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Yuhan Corp, 2022
Opioid-Induced Constipation (OIC) - Dormant Projects, 2022
Opioid-Induced Constipation (OIC) - Discontinued Products, 2022